BioAlliance Pharma Signs a Collaborative Agreement with One of the Worldwide Leaders in Vaccines for a Vaccine Application of Its Patented Lauriad® Mucoadhesive Technology

PARIS--(BUSINESS WIRE)--

Regulatory News:

BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces a collaboration agreement with one of the world leading vaccine companies to develop a vaccine application of its Lauriad^® mucoadhesive technology. The terms of this agreement are not disclosed at this time.

This research program aims at establishing the feasibility of using Lauriad^® technology for vaccination, leading to an efficient needle-free administration based on the application to the gum of this mucoadhesive tablet containing a vaccine antigen. Moreover, this would also avoid the constraints related to manufacturing sterile injectable forms.

This project is carried out within the Fluriad^™ consortium set in March 2011, co-labeled by both “Clusters of excellence” Medicen Paris Region and Atlanpôle Biotherapies and financed up to €2 million by the “Fond Unique Interministériel” (a French program supporting collaborative research projects).

“This collaboration with one of the world leading vaccine companies shows the potential interest of our innovative Lauriad^® system for a needle-free vaccination. This is also a major step taken to increase the value of our proprietary Lauriad^® technology, already validated through three major products of our portfolio: Loramyc^® and Sitavig^®, already registered, and Validive^®, in phase II clinical development,” stated Judith Greciet, CEO of BioAlliance Pharma. “A first successful feasibility would open the way to promising new opportunities in vaccine field with significant market potential worldwide.”

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc^®/Oravig^® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir^®/Sitavig^® (Acyclovir Lauriad^TM) (labialis herpes): Registered in 8 European countries, registration status in the US

Fentanyl Lauriad^TM (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag^® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going

Validive^® (Clonidine Lauriad^TM) (mucositis): Phase II on going

AMEP^® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2011 Reference Document filed with the AMF on April 24, 2012, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).